Real-World Barriers to Molecular Biomarker Testing in Neuro-Oncology Clinical Trials in Resource-Limited Settings: A Scoping Review.
Objectives Molecular biomarkers are crucial for the diagnosis, prognosis, and enrollment in biomarker-driven neuro-oncology clinical trials, but their inequitable availability in low- and middle-income countries (LMICs) hinders uptake of the 2021 WHO Classification of CNS tumours. This scoping review reports an analysi...